KALV
HealthcareKalVista Pharmaceuticals, Inc. · Biotechnology · $1B
What is KalVista Pharmaceuticals, Inc.?
KalVista Pharmaceuticals is a clinical-stage company focused on discovering and developing small molecule protease inhibitors for diseases with significant unmet medical needs. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company has built its pipeline around plasma kallikrein inhibition.
KalVista generates no commercial revenue yet — its business model centers on advancing a pipeline of oral small molecule drugs through clinical trials. The company targets plasma kallikrein, an enzyme implicated in hereditary angioedema (HAE) and diabetic macular edema (DME). Lead programs include sebetralstat, an oral on-demand therapy for HAE attacks currently in Phase 3, and KVD824, another oral HAE candidate. Earlier-stage work includes a Factor XIIa inhibitor program still in preclinical development.
KalVista was founded in 2015 and is headquartered in Cambridge, Massachusetts.
- Sebetralstat — oral on-demand therapy for HAE attacks (Phase 3)
- KVD824 — oral plasma kallikrein inhibitor for HAE
- KVD001 — plasma kallikrein inhibitor studied in DME (Phase 2 complete)
- Factor XIIa inhibitor — preclinical oral program targeting HAE pathway
Is KALV a Good Stock to Buy?
UQS Score rates KALV as Poor overall, reflecting the early-stage nature of its pipeline and the financial profile typical of pre-revenue clinical biotechs.
The one area where KALV stands out within its UQS profile is Risk — the platform rates this pillar as Strong, which for a clinical-stage company often reflects a relatively clean balance sheet or limited near-term debt obligations rather than operational stability.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products, no commercial revenue, and faces an uncertain path to market. Valuation is rated Elevated, suggesting the current market price may already reflect optimistic pipeline assumptions.
Pro members can view the complete pillar breakdown and underlying financial metrics to form a more complete picture of KALV's risk-reward profile. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does KALV pay dividends?
No — KalVista Pharmaceuticals, Inc. does not currently pay a dividend.
KalVista does not pay a dividend, which is standard for clinical-stage pharmaceutical companies. Available capital is directed toward funding clinical trials and research operations. Income-focused investors are unlikely to find KALV suitable; the investment case, if any, rests entirely on pipeline success rather than income generation.
When does KALV report earnings?
KalVista Pharmaceuticals reports financial results on a quarterly cadence, consistent with US-listed equities.
As a pre-revenue company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or earnings metrics. Pipeline milestones and trial readouts tend to move the stock more than any single earnings release.
For the most recent quarter's results and management commentary, visit KalVista's investor relations page directly.
KALV Price History
-28.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in KalVista Pharmaceuticals, Inc.?
Based on KalVista Pharmaceuticals, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
KALV Long-term Outlook
With Growth and Quality both rated Weak, the near-term fundamental outlook for KALV is heavily dependent on binary clinical outcomes rather than organic business expansion. The Strong Risk rating provides some reassurance around financial stability in the short run, but the Elevated Valuation label suggests the market may already be pricing in favorable trial results. Investors should weigh the potential upside of a Phase 3 readout against the real possibility of setbacks that could materially reset expectations.
Growth drivers
- Positive Phase 3 KONFIDENT trial data for sebetralstat in HAE
- Potential regulatory approval and commercialization of an oral HAE therapy
- Expansion of the pipeline into additional indications via the Factor XIIa program
Key risks
- Clinical trial failure or delays across any lead program
- Elevated valuation leaves limited margin of safety if pipeline disappoints
- Ongoing cash consumption with no commercial revenue to offset expenses
KALV vs Peers
KalVista operates in a competitive clinical-stage biotech landscape alongside other small companies pursuing novel therapeutic mechanisms.
ORIC focuses on overcoming cancer treatment resistance, targeting a different therapeutic area than KalVista's HAE and DME programs.
Aktis Oncology pursues targeted radiotherapeutics for cancer, representing a distinct modality and disease focus compared to KalVista's small molecule protease inhibitor approach.
uniQure develops gene therapies for severe diseases, a fundamentally different platform from KalVista's oral small molecule strategy, though both operate in rare and specialty disease spaces.
Frequently Asked Questions
What does KalVista Pharmaceuticals do?
KalVista Pharmaceuticals discovers and develops small molecule protease inhibitors aimed at diseases with limited treatment options. Its primary focus is on plasma kallikrein inhibition, with programs targeting hereditary angioedema and diabetic macular edema. The company is clinical-stage and has not yet commercialized any product.
Does KALV pay dividends?
No, KalVista does not pay a dividend. As a clinical-stage biotech with no commercial revenue, the company directs its capital toward funding research and clinical trials. Dividend income is not part of the KALV investment thesis.
When does KALV report earnings?
KalVista reports on a quarterly cadence typical of US-listed companies. Because it is pre-revenue, reports center on cash position and trial progress rather than traditional earnings. Check KalVista's investor relations page for the latest schedule and results.
Is KALV a good stock to buy?
UQS Score rates KALV as Poor overall. Quality, Moat, and Growth are all Weak, while Valuation is Elevated — a combination that signals meaningful risk relative to the current price. The Strong Risk pillar offers some balance, but the overall profile warrants careful consideration. See the full breakdown on UQS Score Pro.
Is KALV overvalued?
The UQS Valuation pillar for KALV is rated Elevated, suggesting the stock may be pricing in optimistic assumptions about pipeline success. For a company with no approved products and no commercial revenue, valuation is inherently speculative and tied to binary clinical outcomes.
How does KALV compare to its competitors?
KalVista operates alongside other clinical-stage biotechs such as ORIC Pharmaceuticals and uniQure, though each pursues different therapeutic areas and drug modalities. KALV's differentiation lies in its oral small molecule approach to HAE — a relatively underserved market for convenient dosing options.
What is KALV's market cap bracket?
KALV is classified as a small-cap stock. This reflects both its early-stage pipeline and the absence of commercial revenue. Small-cap biotechs typically carry higher volatility and liquidity risk compared to large- or mega-cap peers in the healthcare sector.
Who founded KalVista Pharmaceuticals?
KalVista Pharmaceuticals was founded in 2015. For detailed information on the founding team and company history, the company's official website and public filings provide the most accurate and complete account.
Is KALV a long-term quality investment?
As a long-term quality indicator, the UQS Score rates KALV as Poor. Weak scores across Quality, Moat, and Growth suggest the company has not yet established the durable fundamentals associated with long-term compounding. Pipeline success could change this picture, but the current profile reflects significant uncertainty.
What is the main competitive advantage of KalVista?
KalVista's potential edge lies in its focus on oral, on-demand small molecule therapies for HAE — a space where existing treatments often require injection. If sebetralstat succeeds in Phase 3, an oral option could offer meaningful convenience advantages over current standard-of-care therapies.
What sector does KALV belong to?
KALV belongs to the Healthcare sector, specifically within clinical-stage pharmaceuticals. The company's work on rare diseases like hereditary angioedema places it in a niche but competitive corner of the biotech landscape, where regulatory milestones drive most of the value creation.
Is KALV a growth stock or value stock?
Based on its UQS profile, KALV fits neither category cleanly. Growth is rated Weak given the absence of revenue, while Valuation is Elevated — meaning the stock is not cheap on a fundamental basis. It is best described as a speculative clinical-stage biotech rather than a traditional growth or value play.
Unlock Full KALV Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for KALV
- ✓Access underlying financial metrics and trend data
- ✓Compare KALV against sector peers on every pillar
- ✓Screen for stronger-rated small-cap healthcare stocks
- ✓Get the complete analyst-style quality breakdown
Pro Analysis
KALV — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 39.5 | 8.3 | 23.0 | 52.6 | 82.4 | 58.5 | +8.6 |
| May 7, 2026 | 30.9 | 0.0 | 23.0 | 20.2 | 82.4 | 58.5 | 0.0 |
| May 4, 2026 | 30.9 | 0.0 | 23.0 | 20.2 | 82.4 | 58.6 | +12.4 |
| Apr 22, 2026 | 18.5 | 0.0 | 23.0 | 1.8 | 82.4 | 0.0 | 0.0 |
| Apr 2, 2026 | 18.5 | 0.0 | 23.0 | 2.2 | 82.4 | 0.0 | — |
KALV — Pillar Breakdown
Quality
— 8.3/100 (25%)KalVista Pharmaceuticals, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 52.6/100 (20%)KalVista Pharmaceuticals, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)KalVista Pharmaceuticals, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 58.5/100 (15%)KalVista Pharmaceuticals, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 23/100 (25%)KalVista Pharmaceuticals, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for KALV.
Score Composition
Financial Data
More Stock Analysis
How is the KALV UQS Score Calculated?
The UQS (Unified Quality Score) for KalVista Pharmaceuticals, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses KalVista Pharmaceuticals, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether KalVista Pharmaceuticals, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.